Vestal Point Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001974915
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2026 · 90 positions · Total reported value $3.58B · Top-10 concentration 40.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 14 new · 20 cut · 19 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2026 13F filing, Vestal Point Capital, LP disclosed 90 equity positions with a combined reported value of $3.58B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 40.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2026 were RVMD ($230.97M), BMRN ($201.95M), ABVX ($167.03M). By sector, the heaviest allocations are Health Care 92.0%, Industrials 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+16.5pp), Industrials (+0.8pp) and away from Other (-17.4pp).
Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 47% of names.
The largest new positions opened in Q1 2026 were NBIX ($164.68M), SNY ($67.45M), BSX ($50.20M).
Of the 19 positions fully exited versus the prior quarter, the largest were QQQ ($215.01M), ACLX ($190.71M), DXCM ($84.62M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2026)
- NBIX NEUROCRINE BIOSCIENCES INC · $164.68M
- SNY SANOFI SA · $67.45M
- BSX BOSTON SCIENTIFIC CORP · $50.20M
- COGT COGENT BIOSCIENCES INC · $47.38M
- UTHR UNITED THERAPEUTICS CORP DEL · $44.47M
- DRUG BRIGHT MINDS BIOSCIENCES INC · $35.92M
- PTGX PROTAGONIST THERAPEUTICS INC · $34.38M
- REGN REGENERON PHARMACEUTICALS · $30.91M
Fully Exited (vs previous quarter)
- QQQ INVESCO QQQ TR · prev qtr: $215.01M
- ACLX ARCELLX INC · prev qtr: $190.71M
- DXCM DEXCOM INC · prev qtr: $84.62M
- MRK MERCK & CO INC · prev qtr: $81.58M
- ABT ABBOTT LABORATORIES · prev qtr: $75.17M
- JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $49.30M
- DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $48.46M
- AXSM AXSOME THERAPEUTICS INC. · prev qtr: $38.35M
Insider Transactions (Form 4)
Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-127682 (status: Approved), registered 2023-04-14
- Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: vestalpoint.com
Portfolio Structure
- 63 positions · $3.87B reported value (Q3 2026)
- Top 10 holdings = 67.3% of reported value
- Largest position: ABVX (ABIVAX SA) at 10.1%
- Average position size: $61.44M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.38M | $230.97M | 6.46% | Add | |
| 2 |
|
3.58M | $201.95M | 5.65% | Add | |
| 3 |
|
1.50M | $167.03M | 4.67% | Reduce | |
| 4 |
|
1.25M | $164.68M | 4.60% | New | |
| 5 |
|
2.27M | $142.64M | 3.99% | Add | |
| 6 |
|
3.25M | $127.40M | 3.56% | Reduce | |
| 7 |
|
925.00K | $108.98M | 3.05% | Add | |
| 8 |
|
5.42M | $107.90M | 3.02% | Add | |
| 9 |
|
6.50M | $100.75M | 2.82% | Add | |
| 10 |
|
1.10M | $92.59M | 2.59% | Add | |
| 11 |
|
375.00K | $85.77M | 2.40% | Add | |
| 12 |
|
2.77M | $83.42M | 2.33% | Add | |
| 13 |
|
18.00M | $80.46M | 2.25% | Add | |
| 14 |
|
4.00M | $72.52M | 2.03% | Add | |
| 15 |
|
1.40M | $67.45M | 1.89% | New | |
| 16 |
|
7.03M | $66.88M | 1.87% | Add | |
| 17 |
|
1.32M | $65.11M | 1.82% | Add | |
| 18 |
|
6.17M | $60.76M | 1.70% | Add | |
| 19 |
|
1.00M | $60.65M | 1.70% | Add | |
| 20 |
|
800.00K | $60.28M | 1.69% | Reduce | |
| 21 |
|
3.60M | $59.28M | 1.66% | Add | |
| 22 |
|
1.37M | $55.04M | 1.54% | Add | |
| 23 |
|
1.00M | $52.72M | 1.47% | Reduce | |
| 24 |
|
610.52K | $52.60M | 1.47% | Reduce | |
| 25 |
|
800.00K | $50.20M | 1.40% | New | |
| 26 |
|
481.71K | $49.35M | 1.38% | Add | |
| 27 |
|
1.23M | $47.38M | 1.32% | New | |
| 28 |
|
2.06M | $46.40M | 1.30% | Reduce | |
| 29 |
|
1.44M | $44.94M | 1.26% | Add | |
| 30 |
|
700.00K | $44.76M | 1.25% | Reduce | |
| 31 |
|
75.00K | $44.47M | 1.24% | New | |
| 32 |
|
1.22M | $38.83M | 1.09% | Add | |
| 33 |
|
1.85M | $37.24M | 1.04% | Reduce | |
| 34 |
|
639.90K | $37.21M | 1.04% | Add | |
| 35 |
|
5.00M | $36.00M | 1.01% | Reduce | |
| 36 |
|
492.32K | $35.92M | 1.00% | New | |
| 37 |
|
326.16K | $34.38M | 0.96% | New | |
| 38 |
|
1.77M | $34.05M | 0.95% | Add | |
| 39 |
|
40.00K | $30.91M | 0.86% | New | |
| 40 |
|
100.00K | $29.78M | 0.83% | New | |
| 41 |
|
914.15K | $29.75M | 0.83% | New | |
| 42 |
|
539.27K | $27.82M | 0.78% | New | |
| 43 |
|
1.50M | $27.55M | 0.77% | Hold | |
| 44 |
|
2.17M | $25.85M | 0.72% | New | |
| 45 |
|
4.47M | $25.69M | 0.72% | Hold | |
| 46 |
|
730.00K | $24.44M | 0.68% | New | |
| 47 |
|
2.21M | $22.16M | 0.62% | Add | |
| 48 |
|
285.00K | $20.51M | 0.57% | New | |
| 49 |
|
300.00K | $19.77M | 0.55% | New | |
| 50 |
|
100.00K | $19.72M | 0.55% | New | |
FAQ
What did Vestal Point Capital, LP buy in 2026-Q1?
In its 2026-Q1 13F filing, Vestal Point Capital, LP reported 90 equity positions worth $3.58B in aggregate; its largest disclosed positions were RVMD ($230.97M), BMRN ($201.95M), ABVX ($167.03M).
How large is Vestal Point Capital, LP's portfolio?
Vestal Point Capital, LP reported $3.58B of long equity holdings across 90 positions as of 2026-Q1. Top-10 holdings account for 40.4% of reported value.
What is Vestal Point Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.